Evidence map›Paper›PMID 32463179›Full record

ArticleDiabetes, obesity & metabolism2020

Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study.

Gian Paolo Fadini, Mario Luca Morieri, Enrico Longato, Benedetta Maria Bonora, Silvia Pinelli, Elisa Selmin, Giacomo Voltan, Daniele Falaguasta, Silvia Tresso, Giorgia Costantini and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04542213 (Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor), which is not on this map. Cited by 69 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04542213 phase3completednot on this map

Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19

TypeinterventionalSponsorHospital Regional de Alta Especialidad del BajioRan2020 to 2021Enrolled70ConditionsHyperglycemia, Covid19ArmsLinagliptin tablet, Insulin
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Gian Paolo FadiniDepartment of Medicine, University of Padova, Padova, Italy.ORCID 0000-0002-6510-2097
Mario Luca MorieriDepartment of Medicine, University of Padova, Padova, Italy.
Enrico LongatoDepartment of Information Engineering, University of Padova, Padova, Italy.
Benedetta Maria BonoraDepartment of Medicine, University of Padova, Padova, Italy.
Silvia PinelliDepartment of Medicine, University of Padova, Padova, Italy.
Elisa SelminDepartment of Medicine, University of Padova, Padova, Italy.
Giacomo VoltanDepartment of Medicine, University of Padova, Padova, Italy.
Daniele FalaguastaDepartment of Medicine, University of Padova, Padova, Italy.
Silvia TressoDepartment of Medicine, University of Padova, Padova, Italy.
Giorgia CostantiniDepartment of Medicine, University of Padova, Padova, Italy.
Giovanni SparacinoDepartment of Information Engineering, University of Padova, Padova, Italy.
Barbara Di CamilloDepartment of Information Engineering, University of Padova, Padova, Italy.
Lara TramontanArsenàl.IT, Veneto Region, Treviso, Italy.
Anna Maria CattelanUnit of Infectious Disease, University Hospital of Padova, Padova, Italy.
Andrea VianelloDepartment of Cardiothoracic Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Paola FiorettoDepartment of Medicine, University of Padova, Padova, Italy.ORCID 0000-0003-3445-0387
Roberto VettorDepartment of Medicine, University of Padova, Padova, Italy.
Angelo AvogaroDepartment of Medicine, University of Padova, Padova, Italy.ORCID 0000-0002-1177-0516

Funding

Università degli Studi di Padova
6 · The paper itself

Abstract

Because other coronaviruses enter the cells by binding to dipeptidyl-peptidase-4 (DPP-4), it has been speculated that DPP-4 inhibitors (DPP-4is) may exert an activity against severe acute respiratory syndrome coronavirus 2. In the absence of clinical trial results, we analysed epidemiological data to support or discard such a hypothesis. We retrieved information on exposure to DPP-4is among patients with type 2 diabetes (T2D) hospitalized for COVID-19 at an outbreak hospital in Italy. As a reference, we retrieved information on exposure to DPP-4is among matched patients with T2D in the same region. Of 403 hospitalized COVID-19 patients, 85 had T2D. The rate of exposure to DPP-4is was similar between T2D patients with COVID-19 (10.6%) and 14 857 matched patients in the region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID-19 pneumonia (11.3%) with 351 matched patients with pneumonia of another aetiology (10.3%). T2D patients with COVID-19 who were on DPP-4is had a similar disease outcome as those who were not. In summary, we found no evidence that DPP-4is might affect hospitalization for COVID-19.

Indexed as

AgedAged, 80 and overCase-Control StudiesCOVID-19Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDisease OutbreaksFemaleHospitalizationHumansItalyMaleMiddle AgedPandemicsPrognosisRetrospective StudiesDipeptidyl-Peptidase IV Inhibitorsantidiabetic drug, database research, DPP-4 inhibitor, pharmacoepidemiology

Identifiers

PMID32463179
PMCPMC7283835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.